Publications


Platform: Year: Target:

Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC

Society for Immunotherapy of Cancer (SITC) 2025 November, 2025

Targeting HPV E6/E7 Upregulation of ROR2 with Oz-V in OPSCC

International Papillomavirus Society (IPVS) 2025October, 2025

T-cell Engager in Patients with Treatment Refractory Metastatic Adenocarcinoma

European Society of Medical Oncology (ESMO) 2025October, 2025

First-in-Human Phase 1 Study of a Dual-Conditionally Active Biologic (CAB) EpCAM x CD3 Bispecific T-cell Engager (TCE), BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma

ESMO TAT ASIAJuly, 2025

Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager, BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma

ESMO GI 2025; AWARDED BEST POSTERJuly, 2025

Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a Conditionally Binding CAB-ROR2-ADC, in Patients with Heavily Pretreated Squamous Cell Carcinoma

American Society of Clinical OncologyJune, 2025

BA3361, A Tumor Selective, Conditionally Active anti-Nectin4 ADC with a Novel NextGen Linker System has improved Efficacy in Pancreatic Cancer Models

American Association for Cancer ResearchApril, 2025

Identification of novel senolytic targets and development of Conditionally Active Biologic-based-drug conjugates for targeted senescence-associated secretory phenotype elimination in vivo

American Association for Cancer ResearchApril, 2025

Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate

Antibody TherapeuticsApril, 2025

Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate

mABs JournalApril, 2025

Ozuriftamab Vedotin (BA3021), a Conditionally Binding ROR2-ADC in Patients with Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck: Antitumor Activity Observed Among Patients with Both HPV Related and HPV-Negative Cancers

Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025March, 2025

Exploratory Analysis of Overall Survival among Non-Small Cell Lung Cancer (NSCLC) Patients with Mutated KRAS in a Phase 2 Trial of Mecbotamab Vedotin (CAB-AXL-ADC)

ELCC 2025March, 2025

Updated Results from a Study of Evalstotug (BA3071), an Anti–CTLA-4 Conditionally Active Biologic

AACR IOFebruary, 2025

Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC

International Society of Lung Cancer 2024December, 2024

BA3361, a NextGen CAB ADC Targeting Nectin4

ADC SummitNovember, 2024

Updated Phase 1 and preliminary Phase 2 results from a study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors

Society of Immunotherapy for Cancer (SITC)November, 2024

Evalstotug (BA3071): A potent conditionally active biologic (CAB) anti–CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity.

Society of Melanoma Research 21st International CongressOctober, 2024

Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

European Society of Medical OncologySeptember, 2024

Phase 1 Study of Evalstotug (BA3071), an anti–CTLA-4 Conditionally Active Biologic, in Combination with Nivolumab in Advanced Solid Tumors

American Society of Clinical Oncology (ASCO)June, 2024

Conditionally Active Biologics Targeting Novel Senescence Markers Effectively Eliminate the Senescence-Associated Secretory Phenotype in both In Vitro and in Vivo Models

American Association of Cancer Research (AACR)April, 2024

Development of A Humanized Anti-IL-22 Antibody for Cancer and Inflammation Therapy

American Association of Cancer Research (AACR)April, 2024

Novel Conditionally Active Tetravalent B7-H3 x CD3 T-cell Engagers Targeting Solid Tumors

American Association of Cancer Research (AACR)April, 2024

First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report

JCO Precision OncologyApril, 2024

Novel Conditionally Active Biologic Tetravalent T-Cell Engagers Targeting Solid Tumors

American Association of Cancer Research (AACR)April, 2024

Conditionally Active Biologic (CAB) ADCs with Novel NextGen Linker Show Improved Efficacy and Safety

American Association of Cancer Research (AACR)April, 2024

Results from a Phase 2 Part 1 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Refractory Sarcoma

European Society of Medical Oncology SarcomaMarch, 2024

A Novel Conditional Active Biologic Anti-EpCAM x Anti-CD3 Bispecific Antibody with Synergistic Tumor Selectivity for Cancer Immunotherapy

mABs JournalMarch, 2024

Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC

International Association for the Study of Lung CancerDecember, 2023

A Novel Dual CAB Nectin-4 x CD3 Bispecific Antibody Targeting Solid Tumors

Society of Immunotherapy of CancerNovember, 2023

A Novel Conditionally Active Bispecific HER2 X CD-3 T Cell Engager Targeting Solid Tumors

Society of Immunotherapy of CancerNovember, 2023

Population Pharmacokinetic and Exposure-Response Safety Analyses of Mecbotamab Vedotin (BA3011) in Patients with Advanced Solid Tumors

ASCOMay, 2023

A Novel Dual-Cab Nectin-4 X CD3 Bispecific Antibody Targeting Solid Tumors

American Association for Cancer ResearchApril, 2023

Conditionally Active Biologics Eliminate Senescence Cells in Cancer and Aging

American Association for Cancer ResearchApril, 2023

Novel Conditionally Active Bispecific HER2 X CD3 T-Cell Engager Targeting Solid Tumors

American Association for Cancer ResearchApril, 2023

NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety

American Association for Cancer ResearchApril, 2023

NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety

Antibody Drug Conjugate SummitSeptember, 2022

Interim Safety and Efficacy Results from Phase 1/2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Sarcoma

Connective Tissue Oncology SocietyNovember, 2021

Protein-associated Chemical Switches Differentially Modulate the Binding Activities of Human Apolipoprotein E Isoforms with Their Receptors and with Amyloid Beta Peptides.

Alzheimer’s Association International ConferenceJuly, 2021

Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors

American Association for Cancer ResearchApril, 2021

Novel Conditionally Active Bispecific EpCAM x CD3 T Cell Engagers Targeting Solid Tumors

American Association for Cancer ResearchApril, 2021

Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches

Proceedings of the National Academy of SciencesJanuary, 2021

Novel conditionally active ADCs (CAB ADCs): A novel class of molecules targeting solid tumors

American Association for Cancer ResearchApril, 2020

Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors

American Association for Cancer ResearchApril, 2020

Novel conditionally active biologic (CAB) antibodies

American Association for Cancer ResearchApril, 2019

A Phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL antibody drug conjugate

American Society of Clinical OncologyJune, 2018

Anti-Tumor Efficacy of BA3021

American Association for Cancer ResearchApril, 2018

Anti-Tumor Efficacy of BA3011

American Association for Cancer ResearchApril, 2018

Novel Conditionally Active Biologic anti-Axl ADC Demonstrates Anti-Tumor Efficacy and Improved Safety Profile

American Association for Cancer ResearchApril, 2016